The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps
Phase 2
Not yet recruiting
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Drug: GR1802 injection
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT06015243
Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE
Phase 1
Recruiting
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Biological: low dose GR1603 in phase â… bBiological: low dose GR1603 in phase â…¡Biological: high dose GR1603 in phase â…¡Biological: Placebo in phase â…¡Biological: high dose GR1603 in phaseâ… b
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 136
- Registration Number
- NCT06015230
- Locations
- 🇨🇳
Peking union Medical Hosipital, Beijing, Beijing, China
The Study of Single Dose Administration of GR2002 Injection in Chinese Health Volunteers
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Biological: GR2002 injectionBiological: Placebo
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05954611
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Study of Efficacy and Safety of GR1501 in Patients With Radiographic Axial Spondyloarthritis
Phase 3
Active, not recruiting
- Conditions
- Axial Spondyloarthritis
- Interventions
- Biological: GR1501 low doseBiological: placeboBiological: GR1501 high dose
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 465
- Registration Number
- NCT05881785
- Locations
- 🇨🇳
Peking union Medical Hosipital, Beijing, Beijing, China
The Study of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps
Phase 2
Recruiting
- Conditions
- Chronic Rhinosinusitis with Nasal Polyps
- Interventions
- Biological: placeboBiological: GR1802 injection
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT05873803
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China
Study to Evaluate GR1801's Efficacy and Safety
Phase 3
Recruiting
- Conditions
- Rabies Post-exposure Prophylaxis
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 1200
- Registration Number
- NCT05846568
- Locations
- 🇨🇳
Center for Disease Control and Prevention (CDC), Kunming, Yunnan, China
to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis
Phase 2
Completed
- Conditions
- Axial Spondyloarthritis
- Interventions
- Biological: IL-17A antibody
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT05162937
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath